New studies show risk of COVID-19 hospitalization and death decreases with hydroxychloroquine use

Source: The Blaze, By Aaron Colen

Two recent studies support the effectiveness of hydroxychloroquine as a treatment for COVID-19 that can reduce the chance of hospitalization or death, refuting narratives in the media that the drug is dangerous and being pushed by President Donald Trump for political reasons.

Hydroxychloroquine is a relatively cheap and readily available drug that has been used for decades to treat malaria. Throughout the COVID-19 pandemic, doctors around the world have vouched for positive results seen in patients who take it.

What do the studies say?

study out of Italy found that HCQ reduces by 30% the risk of death for COVID-19 patients who are hospitalized. The result comes from an observational study of more than 3,400 COVID-19 patients in 33 Italian hospitals.

“We observed that patients treated with hydroxychloroquine had a 30% lower in-hospital mortality rate compared to those not receiving this treatment,” said Augusto Di Castelnuovo, epidemiologist at the Neuromed Department of Epidemiology and Prevention, currently at Mediterranea Cardiocentro in Naples.

“Our data were subjected to extremely rigorous statistical analysis, taking into account all the variables and possible confounding factors that could come into play. The drug efficacy was evaluated in various subgroups of patients. The positive results of hydroxychloroquine treatment remained unchanged, especially in those patients showing a more evident inflammatory state at the moment of admission to hospital.”

Another study, which looked at outpatient cases in New Jersey, found that a prescription of hydroxychloroquine reduced the risk of hospitalization by 47%. Because the study was conducted early in the pandemic, when mostly only symptomatic people were being tested, researchers believe their sample of more than 1,200 patients represents people with relatively more advanced cases of COVID-19.

The study concluded that hydroxychloroquine can be effective when given early after a COVID-19 diagnosis, and the study found there was no increase in negative side effects for people who took the drug. One concern about HCQ has been the potential for it to cause heart problems in some patients.

“In this observational study of 1,274 COVID-19 patients, hydroxychloroquine given as an outpatient treatment was associated with a 47% reduction in the hazard of hospitalization,” researchers wrote. “Adverse events were not increased (2% QTc prolongation events, 0% arrhythmias).”

The Food and Drug Administration has cautioned against the use of HCQ outside of hospital or clinical trial settings because of concerns about effects on the heart. The FDA revoked an emergency use authorization for the drug in June.




Related:

Covid-19: The revenge of hydroxychloroquine

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

Belgium Study 8,075 patients: Low HCQ doses resulted in lower mortality in Covid patients

100 doctors go to Brasilia to order hydroxychloroquine from popular pharmacies

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part 3)

Recently Merck issued a stern warning that seemed written by marketing, Kory says, “as it had no scientific data to support the conclusion,” that ivermectin was suddenly dangerous. Another pharmaceutical company’s CEO privately noted that “People must think Merck knows what they’re talking about because it’s their drug,” but Merck has “tremendous disincentives” to say nice things about the generic pill, as it has already spent hundreds of millions of dollars developing an oral anti-viral COVID-19 treatment, rival to ivermectin, that may be priced at $3,000 a dose.

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part 2)

They also restricted the use of essential off-label and generic drugs with blatant disinformation campaigns that reminded Kory of big tobacco’s efforts to hide the dangers of smoking. In effect, the public health authorities eliminated the full toolbox of essential scientific methods and drugs that doctors use every day, including the most effective early, prophylactic, and late-stage treatments for COVID-19, which were developed by frontline doctors, not pharmaceutical companies.

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part I)

In the professor’s continual review of “the latest (and best) literature,” he picked up a surprising “data signal” in October from emerging studies in Latin America. ivermectin, a safe, cheap, FDA-approved anti-parasitic drug, was showing remarkable anti-viral and anti-inflammatory activity as a repurposed drug—the most powerful COVID-19 killer known to science. 

Read More »